B. Riley Lifts Earnings Estimates for Kymera Therapeutics

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at B. Riley lifted their Q2 2025 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Monday, May 12th. B. Riley analyst K. Patel now forecasts that the company will post earnings per share of ($1.01) for the quarter, up from their prior forecast of ($1.02). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.85) EPS, FY2026 earnings at ($3.88) EPS, FY2027 earnings at ($3.88) EPS and FY2028 earnings at ($3.80) EPS.

A number of other analysts also recently issued reports on KYMR. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Guggenheim reissued a “buy” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research report on Monday. Citigroup initiated coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective for the company. Finally, UBS Group lowered their target price on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.27.

Kymera Therapeutics Trading Down 3.2%

Shares of NASDAQ:KYMR opened at $31.14 on Wednesday. The business has a 50-day moving average price of $29.55 and a 200 day moving average price of $37.36. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -13.31 and a beta of 2.18. Kymera Therapeutics has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company’s quarterly revenue was up 114.6% on a year-over-year basis. During the same period last year, the company earned ($0.69) EPS.

Insider Activity

In related news, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. The trade was a 3.37% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYMR. Wellington Management Group LLP lifted its stake in Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after purchasing an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C purchased a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $23,856,000. Boxer Capital Management LLC purchased a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $17,098,000. Finally, Janus Henderson Group PLC lifted its stake in Kymera Therapeutics by 2,397.9% in the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after buying an additional 362,276 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.